Functional Hypercortisolism in Type 2 Diabetes: The Endocrine Cortico‑Metabolic Amplifier (ECMA) Theory

Background: A substantial subset of patients with difficult-to-control Type 2 Diabetes (T2D) exhibits biochemical evidence of hypercortisolism. Here we propose a unifying, testable model-the Endocrine Cortico‑Metabolic Amplifier (ECMA)-that explains why functional hypercortisolism emerges, how it worsens insulin resistance and hyperglycemia and why glucocorticoid receptor antagonism improves glycemic control in this phenotype. Hypothesis: Chronic hyperinsulinemia upregulates Hypothalamic‑Pituitary‑Adrenal (HPA) axis drive, creating a state of functional hypercortisolism. Intracrine regeneration of cortisol in adipose tissue via 11β‑HSD1 and in subgroups, Mild Autonomous Cortisol Secretion (MACS) from adrenal incidentalomas add to systemic glucocorticoid action. Cortisol then promotes hepatic gluconeogenesis and skeletal muscle insulin resistance, amplifying visceral adiposity and hyperinsulinemia-closing a self reinforcing loop. Evidence: The prevalence and treatment phases of the CATALYST program identified ~1 in 4 uncontrolled T2D patients with hypercortisolism under standardized screening and showed clinically meaningful A1c reductions with glucocorticoid receptor antagonism. Convergent evidence links OSA/sleep disruption and stress‑related disorders to increased HPA activation, while clinical and translational data support 11β‑HSD1 as an adipose amplifier of glucocorticoid action. Implications: ECMA reframes functional hypercortisolism as both marker and amplifier-causal enough to be therapeutically tractable. We propose a pragmatic screening‑to‑treat algorithm and a research agenda to refine patient selection and endpoints.